+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

GLP-1R Agonists - Label Extensions/Drug Repurposing: Market Overview

  • PDF Icon

    Report

  • 73 Pages
  • April 2025
  • Region: Global
  • GlobalData
  • ID: 6086743
This report is a market overview of GLP-1R agonists, focusing on their potential repurposing and label expansions in diseases outside type 2 diabetes and obesity.

The potential of GLP-1RAs is based on their insulin sensitization and anti-inflammatory properties.
GLP-1RAs are being investigated in different diseases in the metabolic, neurologic, and cardiologic markets.
Novo Nordisk and Eli Lilly are currently the major players in the GLP-1RA space, but opportunity remains for new entrants.

Scope

  • Overview of GLP-1R agonists, including marketed GLP-1RAs and diseases under investigation.
  • Analysis of unmet needs, challenges and opportunities in GLP-1RAs repurposing.
  • Pipeline analysis and opportunity assessment of GLP-1RAs in different therapeutic areas.
  • Overview of current major players in the GLP-1RAs space and potential future players.
  • GLP-1RAs global market outlook and deals overview.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the GLP-1RAs therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GLP-1RAs therapeutics market in the future.
  • Identify the major challenges and opportunities in the GLP-1RA space and the potential of this therapeutic class in multiple indications.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Preface
1.1 Contents
1.2 Abbreviations
1.3 Related Reports
2 Executive Summary
3 GLP-1R Agonists Overview
3.1 What Are GLP-1R Agonists
3.2 GLP-1R in the Body
3.3 History of GLP-1R Agonists
4 Industry Trends
4.1 Oral GLP-1Ras
4.2 Lower Dosing Frequency
4.3 Combination and Dual/Triple Agonists
4.4 Repurposing GLP-1Ras
5 Marketed Products
5.1 Global GLP-1RA Marketed Landscape
5.2 Marketed GLP-1Ras
5.3 Challenges and Opportunities in GLP-1RA Repurposing
5.4 Key Opinion Leader Perspectives on GLP-1RA Unmet Needs
6 Pricing and Reimbursement Assessment Case Study: Ozempic
7 Pipeline Analysis
7.1 Top 20 Indications with GLP-1RAs in Development
7.2 Top Five Therapeutic Areas with the Most GLP-1RA Pipeline Assets
7.3 GLP-1RA Pipeline Candidates
7.4 Where Are GLP-1RAs Expected to Position in the Future Chronic Kidney Disease Treatment Landscape?
7.5 Where Are GLP-1RAs Expected to Position in the Future Heart Failure Treatment Landscape?
7.6 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment for Heart Failure and Chronic Kidney Disease
7.7 GLP-1RA Opportunities Beyond Planned Label Expansions
7.8 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Polycystic Ovary Syndrome
8 Opportunities and Challenges
8.1 Opportunities: the Role of GLP-1RAs in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
8.2 Opportunities: GLP-1RAs in Liver Diseases
8.3 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Liver Diseases
8.4 Opportunities: the Role of GLP-1RAs in Neurodegenerative Diseases
8.5 Opportunities: GLP-1RAs in Central Nervous System Disorders
8.6 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Parkinson’s Disease
8.7 Opportunities: the Role of GLP-1RAs in Diastolic Heart Failure and Stroke
8.8 Opportunities: GLP-1RAs in Cardiovascular Diseases
8.9 Opportunities: the Role of GLP-1RAs in Chronic Kidney Disease
8.10 Opportunities: GLP-1RAs in Other Diseases
9 Companies
9.1 Current Major Player: Novo Nordisk
9.2 Current Major Player: Eli Lilly
9.3 Potential Future Players
9.4 Key Opinion Leader Perspectives on Future Players in the GLP-1RA Space
10 Market Outlook and Deals
10.1 GLP-1RA Global Market
10.2 Top 20 Major Deals and Acquisitions Between 2022 and 2025 with GLP-1Ras
11 Appendix
11.1 Bibliography
11.2 Primary Research - KOL Information
11.3 About the Authors
12 Contact the Publisher

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Novo Nordisk AS
  • Eli Lilly and Co
  • Shanghai Minwei Biotechnology Co Ltd
  • Metsera Inc
  • Sihuan Pharmaceutical Holdings Group Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • AstraZeneca Plc
  • PegBio Co Ltd
  • Beijing QL Biopharmaceutical Co Ltd
  • Sciwind Biosciences Co Ltd
  • U.S. National Institutes of Health
  • Boehringer Ingelheim International GmbH
  • i2O Therapeutics Inc
  • Zhejiang Doer Biologics Corp
  • CSPC Pharmaceutical Group Ltd
  • Peptron Inc
  • Carmot Therapeutics Inc
  • Amogen Pharma Pvt Ltd
  • BioLingus AG
  • The United Laboratories International Holdings Ltd
  • Tonghua Dongbao Pharmaceutical Co Ltd
  • Annovis Bio Inc
  • ImmunoForge Co Ltd
  • Biogenomics Ltd
  • China Pharmaceutical University
  • Zhejiang Heze Pharmaceutical Technology Co Ltd
  • Zhuhai United Laboratories Co Ltd
  • Hangzhou Jiuyuan Gene Engineering Co Ltd
  • Structure Therapeutics Inc
  • Altimmune Inc
  • Chia Tai Tianqing Pharmaceutical Group Co Ltd
  • Gmax Biopharm LLC
  • Guangzhou Dazhou Biomedical Technology Co Ltd
  • Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
  • Huadong Medicine Co Ltd
  • Innovent Biologics Inc
  • Merck & Co Inc
  • Neuraly Inc
  • Onegene Biotechnology Inc
  • Protheragen Inc
  • RenaissThera Pvt Ltd
  • Sekkei Inc
  • Uni-Bio Science Group Ltd
  • HEC Pharma Co Ltd
  • Jiangsu Hansoh Pharmaceutical Group Co Ltd
  • Cascade Pharmaceuticals Inc
  • D&D Pharmatech Co Ltd
  • Huons Global Co Ltd
  • Immunwork Inc
  • Leto Laboratories Co Ltd
  • MetaVia Inc
  • Pfizer Inc
  • Qilu Regor Therapeutics Inc
  • Sanofi
  • Xintrum Pharmaceuticals Ltd
  • Gan & Lee Pharmaceuticals Co Ltd
  • Adocia SAS
  • AnyGen Co Ltd
  • Ascendis Pharma AS
  • AULBIO Co Ltd
  • BrightGene Bio-Medical Technology Co Ltd
  • Camurus AB
  • HK inno.N Corp
  • Hybio Pharmaceutical Co Ltd
  • IGC Pharma Inc
  • Lancaster University
  • Laxxon Medical GmbH
  • Poolbeg Pharma Plc
  • ProGen Co Ltd
  • Septerna Inc
  • Shanghai Innogen Pharmaceutical Technology Co Ltd
  • Shenzhen Salubris Pharmaceuticals Co Ltd
  • Sun Pharmaceutical Industries Ltd
  • Suzhou Wingtech Pharmaceutical Technology Co Ltd
  • Theertha Biopharma Pvt Ltd
  • Verdiva Bio Ltd
  • Vivani Medical Inc
  • Yunovia Co Ltd
  • Adare Pharma Solutions
  • Amgen Inc
  • Apeloa Pharmaceutical Co Ltd
  • ApicHope Pharmaceutical Co Ltd
  • Arecor Therapeutics Plc
  • Biolexis Therapeutics Inc
  • Biomea Fusion Inc
  • Biomed Industries Inc
  • BioNxt Solutions Inc
  • California Institute for Biomedical Research
  • China Medical System Holdings Ltd
  • Chongqing Chenan BioPharm Co Ltd
  • CinFina Pharma LLC
  • Crinetics Pharmaceuticals Inc
  • CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
  • Daewoong Therapeutics Inc
  • Diabetology (Products) Ltd
  • Dx&Vx
  • Efil Bioscience Inc
  • Entera Bio Ltd
  • Gilead Sciences Inc
  • Guangzhou BeBetter Medicine Technology Co Ltd
  • HangZhou HuiSheng Biotech Pharmaceutical Co Ltd
  • Hepagene Therapeutics Inc
  • HighField Biopharmaceuticals, Inc.
  • Hua Medicine Shanghai Ltd
  • INVENT Pharmaceuticals Inc
  • Inventage Lab Inc
  • iX Biopharma Ltd
  • Jiangsu Normal University
  • Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd
  • Livzon Pharmaceutical Group Inc
  • MeiraGTx Holdings Plc
  • MindRank Ltd
  • Niedlfree Technologies Pvt Ltd
  • OPKO Health Inc
  • Remedium Bio Inc
  • Scohia Pharma Inc
  • Shandong New Era Pharmaceutical Co Ltd
  • SN BioScience Co Ltd
  • Tharimmune Inc
  • Viking Therapeutics Inc
  • vTv Therapeutics Inc
  • Youngene Therapeutics Co Ltd
  • Zealand Pharma AS
  • 4Moving Biotech
  • Abaxys Therapeutics SA
  • Aerami Therapeutics Holdings Inc
  • AI Proteins Inc
  • Akrikhin
  • Alphamab Oncology
  • Aprilbio Co Ltd
  • Ascletis Pharma Inc
  • Beijing Eastern Biotech Co Ltd
  • Beijing SL Pharmaceutical Co Ltd
  • Biora Therapeutics Inc
  • Bostal Drug Delivery Co Ltd
  • Bristol-Myers Squibb Co
  • Chengdu Brilliant Pharmaceutical Co Ltd
  • China Resources Double-Crane Pharmaceutical Co Ltd
  • Closed Loop Medicine Ltd
  • Coya Therapeutics Inc
  • Delpor Inc
  • Duke University
  • Enteris BioPharma Inc
  • G2GBIO Inc
  • GlyTech Inc
  • Gubra ApS
  • Halo Therapeutics Ltd
  • HEC Pharm Group
  • Hualan Biological Engineering Inc
  • Iconovo AB
  • Icure Pharmaceutical Inc
  • Imagine Pharma LLC
  • Immupharma Plc
  • Imperial College London
  • Innopharmax Inc
  • Jiangsu Wanbang Biochemical Pharmaceutical Group Co Ltd
  • Kailera Therapeutics Inc
  • Kariya Pharmaceuticals IVS
  • Kunming Yinnuo Medical Technology Co. Ltd.
  • Lanzhou Institute of Biological Products Co Ltd
  • Lepu Medical Technology (Beijing) Co Ltd
  • Mapi Pharma Ltd
  • MBX Biosciences Inc
  • Metaphore Biotechnologies Inc
  • Nanexa AB
  • National Institute of Biomedical Imaging and Bioengineering
  • NutriBand Inc
  • Oramed Pharmaceuticals Inc
  • Original BioMedicals Co Ltd
  • Pep2Tango Therapeutics Inc
  • ProLynx LLC
  • Qilu Pharmaceutical Co Ltd
  • QuiaPEG Pharmaceuticals AB
  • Rani Therapeutics LLC
  • Rivus Pharmaceuticals Inc
  • Rose Pharma Inc
  • R-Pharm
  • Sail Biomedicines Inc
  • Shandong Boan Biotechnology Co Ltd
  • Shanghai Fosun Pharmaceutical (Group) Co Ltd
  • Sino Biopharmaceutical Ltd
  • Syracuse University
  • Terns Pharmaceuticals Inc
  • Terry Suzhou Pharmaceutical Co Ltd
  • The University of Adelaide
  • Twist Bioscience Corp
  • University of Padova
  • University of Ulster
  • Vanderbilt University
  • Virtici LLC
  • Wuxi Hebang Biotechnology Co Ltd
  • Yichang Humanwell Pharmaceutical Co Ltd
  • Yonsei University College of Medicine
  • Zhejiang HuaYang Pharmaceutical Co Ltd
  • Zhongshan Wanhan Pharmaceutical Co Ltd